Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 1998

View Archived Issues

Therapeutic Antibodies updates pipeline

Company Profile: PPL Therapeutics

Elan updates nicotine patch studies and its late-stage development pipeline

VIMRx and Columbia terminate research agreements

Pfizer: analysts' meeting highlights

Potent antifungal triazoles reported by Sankyo

Astra claims novel NOS inhibitors for asthma, rheumatoid arthritis and pain

Central muscarinic receptor agonists patented by U. of Toledo

Phase II clinical trial demonstrates ALX1-11 effective in treating osteoporosis

Novel compounds from P&G behave as alpha2-adrenoceptor agonists

Japanese lab prepares new, broad-spectrum carbapenems

Biomira initiates pivotal phase III trial of Theratope vaccine

StressGen's protein fusion vaccines elicit potent immune response without additional adjuvants

CuraGen, Glaxo Wellcome initiate collaborative pharmacogenomics-based drug discovery effort

Patent covering cytokine trap technology issued to Regeneron

Isis patents antisense oligonucleotides for cancer treatment

FDA approves Sandostatin LAR once-monthly depot formulation

PSC-833 plus chemotherapy is safe and effective in older patients with AML

Safer and more effective SERM compounds reported in development at Signal

Photogen initiates development of ocular disease Rx; receives U.S. patents for technology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.